Insomnia Treatment Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Insomnia Treatment Market Trends and Insights

Aging population with comorbid sleep disorders

One in four adults aged 65-79 years reports chronic insomnia, versus 16% in younger cohorts. Age-related polypharmacy, cognitive decline, and cardiovascular comorbidities complicate care and elevate interest in orexin antagonists, which preserve sleep architecture without marked next-day impairment. The 2025 FDA approval of suvorexant for mild-to-moderate Alzheimer’s dementia enlarged the elder addressable pool and validated age-specific dosing strategies. Pharma pipelines now prioritize geriatric-friendly formulations to capture this expanding segment.

Commercial launch of next-gen orexin antagonists

Daridorexant and lemborexant have shifted treatment focus from GABA modulation to orexin pathway inhibition, reducing sleep latency by up to 35 minutes and trimming wake-after-sleep onset by 29 minutes in pivotal trials. China’s 2025 approval of DAYVIGO opened a 172.5 million-patient market, underscoring global appetite for this mechanism. Patent protection to 2033 shields innovators, giving them margin headroom and investment runway.

Expansion of digital CBT-I platforms via telehealth

Digital CBT-I delivers symptom remission in 76% of users and cuts sleep onset time by 54%. The American Academy of Sleep Medicine’s 2024 call for permanent telehealth coverage legitimizes virtual insomnia care. Partnerships such as Green Shield Canada–HALEO show 94% clinical resolution after five-week protocols and illustrate payer acceptance. Wearable integration provides objective sleep metrics, strengthening clinical credibility.

Expansion of digital CBT-I platforms via telehealth

Digital CBT-I delivers symptom remission in 76% of users and cuts sleep onset time by 54%. The American Academy of Sleep Medicine’s 2024 call for permanent telehealth coverage legitimizes virtual insomnia care. Partnerships such as Green Shield Canada–HALEO show 94% clinical resolution after five-week protocols and illustrate payer acceptance. Wearable integration provides objective sleep metrics, strengthening clinical credibility.

Patent expiries driving rapid generic erosion

Zolpidem’s loss of exclusivity spawned 13 generic approvals and re-set price points, illustrating margin compression that typically reaches 80% within 18 months. Branded holders counter via extended-release formats and lifecycle tactics, but the effect remains a net drag on premium drug revenue. The 2024 sale of Ambien brands to Cosette for USD 39 million signals continuing though diminished brand equity in post-LOE environments.

Dependency & safety concerns of hypnotics

Stronger U.S. boxed warnings on complex sleep behaviors and European data showing 17.8-week average Z-drug use despite 4-week guidance intensify prescriber caution. Falls in elderly populations and cognitive impairment risks shift preference toward shorter courses, non-pharmacological care, or newer orexin options with cleaner safety profiles.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Treatment Type: Pharmacological Dominance Faces Digital Disruption

The pharmacological segment generated 76.72% of insomnia treatment market revenue in 2025 given entrenched prescribing habits and rapid symptom relief expectations. Non-benzodiazepine Z-drugs and legacy benzodiazepines comprised most scripts, but orexin receptor antagonists captured a growing slice following multiple 2024-2025 approvals. Non-pharmacological solutions, led by digital CBT-I, delivered the fastest growth at a 5.39% CAGR, reflecting payer acceptance and consumer preference for non-drug options. Over-the-counter products, including cannabidiol, attracted self-medicating users reporting 62.9% sleep-quality improvement.

Converging care models now bundle drugs with sleep-coaching apps, remote monitoring, and behavioral nudges to optimize adherence. Prescription digital therapeutics cleared by the FDA validate reimbursement and set the stage for hybrid regimens that improve long-term efficacy. Companies with integrated platforms tap dual revenue streams while strengthening real-world evidence packages demanded by payers. The shift implies rising competition on holistic outcomes rather than molecule-level distinctions, rewarding firms that marry pharmacology with technology.

By Insomnia Type: Comorbid Cases Drive Growth

Primary insomnia delivered 61.88% of 2025 revenue yet grows slower than comorbid insomnia, which is forecast to expand at 5.98% CAGR and widen its contribution to the insomnia treatment market size through 2031. Multi-morbidity involving depression, anxiety, and cardiovascular disease calls for coordinated management strategies and favors medications with minimal interaction liabilities such as orexin antagonists. The 2025 label expansion of suvorexant to Alzheimer’s dementia elevated disease-specific opportunities and spurred research into neurodegenerative comorbidities.

Digital therapeutics capable of addressing both insomnia and underlying mood disorders through targeted modules strengthen the value proposition for integrated care. Insurers increasingly reimburse bundled solutions that treat root causes, encouraging health-system partnerships. As healthcare shifts toward outcome-based reimbursement, comorbid cases become a strategic growth lever given their higher overall economic burden.

By Patient Age Group: Adult Segment Leads, Pediatric Shows Promise

Adults aged 18-64 years accounted for 56.13% of 2025 revenue, underpinned by work stress and employer benefits that facilitate treatment access. The insomnia treatment market share among geriatric patients is rising due to aging demographics, but dosing complexities and fall risk necessitate differentiated formulations. Pediatrics, while under 10% of current prescriptions, is projected to chart a 5.83% CAGR as clinicians recognize the developmental impact of chronic sleep loss. Ongoing trials for daridorexant in adolescents could unlock pediatric labeling and broaden therapeutic reach.

Wearables appeal across age groups but hold particular promise for adolescents and young adults accustomed to mobile health ecosystems. For older adults, simplified dosing and clear safety profiles remain decisive. Market entrants that tailor delivery forms—liquid suspensions, low-dose tablets, or chewables—stand to build early franchise strength in pediatric segments.

By Care Setting: Outpatient Dominance, Homecare Acceleration

Outpatient clinics and ambulatory centers generated 63.27% of 2025 revenue as most insomnia evaluations and prescriptions occur in community settings. Hospital inpatient demand is limited to severe, comorbid, or postoperative cases. Telehealth-enabled homecare is the fastest-growing channel at 6.14% CAGR, supported by payer coverage for virtual CBT-I and remote monitoring. FDA-cleared overnight oximetry wearables allow clinicians to titrate doses without in-person visits, cutting costs and accommodating patient preference for home-based care.

Sleep clinics maintain a role for polysomnography and complex differential diagnosis. However, as insurers cap reimbursements for in-lab testing, clinics are diversifying into subscription-based virtual coaching and device sales. Vendors that supply integrated hardware-software ecosystems to clinics and patients capture value across the care continuum.

Geography Analysis

North America’s leadership rests on sophisticated payer systems, employer wellness integration, and the FDA’s supportive stance toward digital therapeutics. North America accounted for 37.64% of 2025 revenue. Medicare covers key sleep studies but still excludes chronic insomnia polysomnography, encouraging uptake of lower-cost home studies. Europe provides reliable but slower growth; the EMA approved daridorexant yet rejected ramelteon, reflecting stringent evidence standards. Adoption gaps remain, with benzodiazepines often over-prescribed despite guideline limits. 

Asia-Pacific outpaces other regions at a 6.63% CAGR; China’s 2025 lemborexant launch and South Korea’s ongoing daridorexant Phase 3 trial exemplify rapid regulatory movement. Japan’s early embrace of orexin agents demonstrates high physician receptivity, while Australia’s telehealth expansion widens rural access. Cannabinol products, legal since 2020 in Japan, present a parallel over-the-counter market and compel prescription brands to differentiate on clinical data. South America and the Middle East remain nascent but invest in diagnostic infrastructure, positioning them for above-average long-term growth. Multinationals cultivate local generics alliances to navigate pricing and distribution complexities in these regions.

Regulatory Landscape

Regulation spans prescription hypnotics, controlled-substance oversight, and emerging digital therapeutics pathways. In the United States, FDA labeling and post-market controls continue to shape use of long-standing Z-drugs. Updated zolpidem tartrate labeling became effective in January 2026, reinforcing short-term use guidance and interaction warnings that influence prescriber behavior and payer utilization management. FDA actions also affect competitive intensity in mature molecules, such as the July 2026 determination that TOVALT ODT (zolpidem tartrate) was not withdrawn for safety or efficacy, which supports continued ANDA activity for comparable formulations.

In Europe, the EMA and EU institutions are tightening evidence requirements and refining system-wide rules. The EMA CHMP confirmed in March 2026 its refusal (on re-examination) to expand Hetlioz (tasimelteon) for pediatric sleep disturbances in Smith-Magenis syndrome, signaling a high bar for pediatric sleep-related indications. Separately, the European Parliament and Council reached political agreement in December 2025 on reform of EU pharmaceutical legislation, setting up a multi-year (2026-2028) transition that marketing authorization holders must track for changes affecting development incentives, authorization processes, and lifecycle compliance across EU member states.

Value Chain Analysis

The value chain starts with discovery and clinical development (including orexin-pathway innovation and digital CBT-I program design), then moves through regulatory submission, API and finished-dose manufacturing, packaging, and distribution to hospitals, sleep clinics, retail pharmacies, and increasingly direct-to-patient telehealth channels for behavioral therapy. For established pharmacological therapies, cost and continuity depend heavily on API sourcing and controlled-substance compliance. Schedule IV insomnia drugs such as zolpidem and lemborexant operate under quota systems (for example, DEA aggregate and individual manufacturing quotas in the United States), which can cap production independent of demand and requires careful capacity planning.

Recent supply-side actions show a shift from cost-optimized to resilience-focused networks as orexin antagonist volumes broaden geographically. Nxera Pharma received manufacturing approval in October 2025 to add an API site in Asia to support QUVIVIQ (daridorexant) supply for Japan and wider APAC, illustrating how innovators and partners are building redundancy as commercialization expands. Downstream, payer requirements and channel mix (outpatient, homecare, and digital therapeutics) increase the role of real-world evidence generation, adherence programs, and device or app integration, pushing manufacturers and platform providers to coordinate pharmacovigilance, patient support, and distribution logistics across multiple jurisdictions.

Market Opportunities and Future Outlook

Orexin-mechanism expansion across new geographies and patient segments is opening whitespace beyond legacy hypnotics, especially where regulators and payers scrutinize long-term safety and next-day functioning. In China, Sky Pharma launched Fazamorexant Tablets (Mengping) in May 2026 as a domestic dual orexin receptor antagonist for adult insomnia, adding local competition and broadening category access in a market already primed by prior orexin approvals. In Europe, Eisai's UK MHRA acceptance (July 2026) of a marketing authorization application for lemborexant creates a concrete pathway to expand access in a major non-EU European market, with likely knock-on effects for regional pricing, supply planning, and medical education investments.

Non-pharmacological and hybrid care models are moving from adjunct to reimbursable frontline options, supported by regulatory clearance and telehealth normalization. Big Health received US FDA clearance for SleepioRx in August 2024, reinforcing the prescription digital therapeutic route for chronic insomnia and encouraging payers and employer plans to consider app-based CBT-I as an alternative or complement to drug therapy. Pediatric and comorbid-insomnia programs also represent near-term development whitespace: Idorsia reported statistically significant Phase 2 results for daridorexant in pediatric insomnia (ages 10-18) in March 2026, and EMA activity such as the April 2024 acceptance of a modified pediatric investigation plan for seltorexant underscores ongoing regulatory engagement around adolescent populations with insomnia symptoms.